Global Hereditary Angioedema Treatment Market Size By Type (C1 Estearse Inhibitors (Plasma Products, Recombinant Products)), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Seg...

The Global Hereditary Angioedema (HAE) Treatment Market was valued at USD 2.1 billion in 2023 and is projected to surpass USD 5.4 billion by 2031, growing at a CAGR of 12.6% during the forecast period from 2023 to 2031. The market is witnessing robust growth due to increasing awareness, early diagnosis, and the rising availability of advanced treatment options. Hereditary angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling, is gaining clinical attention, thereby driving pharmaceutical investments and innovation in targeted therapies.

Drivers:

1. Rising Prevalence and Awareness of Rare Diseases:

Enhanced global surveillance and rare disease registries are enabling better identification and tracking of HAE patients. This, coupled with public and private awareness campaigns, has resulted in early diagnosis and access to treatment.

2. Technological Advancements in Biologics and Gene Therapy:

Recent developments in monoclonal antibodies and plasma-derived therapies are significantly improving the efficacy of HAE treatments. Furthermore, emerging gene therapies are being studied for long-term cures, adding a transformative dimension to the market.

3. Regulatory Incentives and Orphan Drug Designation:

Governments and regulatory bodies are supporting the HAE treatment market by granting orphan drug status to new therapeutics, offering tax benefits, market exclusivity, and fast-track approvals that encourage R&D investments.

Restraints:

1. High Cost of Treatment:

HAE therapies, particularly biologics and prophylactic treatments, come with high price tags that can limit accessibility, especially in low- and middle-income countries. This continues to be a significant barrier to market expansion.

2. Limited Awareness in Emerging Economies:

Despite advancements in developed nations, awareness and diagnosis rates in regions like Africa and parts of Asia remain low, hindering patient reach and slowing adoption of advanced therapies.

Opportunity:

1. Expansion of Prophylactic Therapies and At-Home Treatment Solutions:

The growing adoption of at-home treatment regimens and self-administered prophylactic therapies is expected to drive long-term adherence, reduce hospital visits, and improve patient quality of life.

2. Emerging Markets and Strategic Collaborations:

Untapped markets in Latin America, Asia-Pacific, and the Middle East present new opportunities. Strategic collaborations between biotech firms and regional healthcare providers can facilitate quicker market entry and distribution.

Market by System Type Insights:

Based on treatment type, the C1-inhibitor replacement therapy segment dominated the market in 2023, attributed to its proven efficacy in both acute and preventive treatments. However, the kallikrein inhibitor segment is expected to grow at the fastest rate due to the introduction of newer subcutaneous and oral formulations that enhance patient compliance.

Market by End-use Insights:

In terms of end-use, hospitals and specialty clinics accounted for the largest market share in 2023 due to their ability to administer acute-phase interventions and manage complex HAE cases. Meanwhile, homecare settings are projected to exhibit the highest CAGR, supported by the rising trend of at-home self-administration therapies.

Market by Regional Insights:

North America led the global market in 2023, driven by high diagnostic rates, a robust healthcare infrastructure, and the presence of leading pharmaceutical companies. However, Asia-Pacific is expected to witness the fastest growth during the forecast period, owing to increasing healthcare expenditure, improving disease awareness, and regulatory reforms.

Competitive Scenario:

Key players in the Global Hereditary Angioedema Treatment Market include Takeda Pharmaceutical Company Limited, CSL Behring, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Pharming Group NV, KalVista Pharmaceuticals, Attune Pharmaceuticals, and Adverum Biotechnologies. These companies are actively engaging in clinical trials, strategic partnerships, and product launches to consolidate their market positions.

In 2023, BioCryst Pharmaceuticals launched Orladeyo® (berotralstat) in several new markets, enhancing its global footprint.

CSL Behring is expanding access to Haegarda®, a subcutaneous C1-INH therapy, by launching awareness programs targeting early diagnosis.

Scope of Work – Global Hereditary Angioedema Treatment Market

Key Market Developments:

2023: Takeda announced results from a Phase 4 study showing long-term efficacy of Takhzyro® for HAE prophylaxis.

2024: Pharming received approval to commercialize RUCONEST® in additional EU countries.

2025: KalVista began Phase 3 trials for its oral kallikrein inhibitor, targeting patients preferring pill-based treatments.

FAQs:

1) What is the current market size of the Global Hereditary Angioedema Treatment Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Hereditary Angioedema Treatment Market?

Key growth drivers include increasing diagnosis rates and innovations in prophylactic biologics and gene therapies.

3) Which is the largest region during the forecast period in the Global Hereditary Angioedema Treatment Market?

North America is expected to maintain its dominance due to advanced healthcare systems and early adoption of therapies.

4) Which segment accounted for the largest market share in Global Hereditary Angioedema Treatment Market?

The C1-inhibitor replacement therapy segment led the market in 2023.

5) Who are the key market players in the Global Hereditary Angioedema Treatment Market?

Key players include Takeda, CSL Behring, BioCryst, Pharming, Ionis Pharmaceuticals, and KalVista.